Clinical Trial Update: Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial assessing donor-derived CD19 CAR T therapy bridging allogeneic HSCT, followed by donor-derived CD22 CAR T therapy, for relapsed/refract…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• donor-derived CD19 CAR T therapy (CD19 CAR T cells)
• donor-derived CD22 CAR T therapy (CD22 CAR T cells)

Snippet

Sponsor: Beijing GoBroad Hospital | Conditions: B-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse | Phase 1 | Status: RECRUITING